Barclays PLC Buys 48,313 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Barclays PLC grew its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 280.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,561 shares of the biotechnology company’s stock after acquiring an additional 48,313 shares during the quarter. Barclays PLC’s holdings in Aldeyra Therapeutics were worth $353,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Perceptive Advisors LLC increased its stake in Aldeyra Therapeutics by 7.9% during the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after purchasing an additional 682,265 shares in the last quarter. State Street Corp increased its position in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after acquiring an additional 16,188 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its holdings in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after acquiring an additional 295,864 shares during the last quarter. International Assets Investment Management LLC lifted its position in Aldeyra Therapeutics by 397.0% in the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after acquiring an additional 229,487 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Aldeyra Therapeutics by 21.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 34,885 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Trading Up 1.3 %

ALDX stock opened at $4.84 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. Aldeyra Therapeutics, Inc has a 1-year low of $2.71 and a 1-year high of $6.55. The business has a fifty day moving average price of $4.94 and a 200-day moving average price of $4.98.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). On average, equities research analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 EPS for the current year.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.